FSD Pharma Inc. (HUGE) |
| 0.0899 -0.01 (-10.1%) 08-14 16:00 |
| Open: | 0.095 |
| High: | 0.1042 |
| Low: | 0.087 |
| Volume: | 22,015,006 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.01 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 21.06 |
| Resistance 1: | 20.24 |
| Pivot price: | 19.59 |
| Support 1: | 18.91 |
| Support 2: | 15.73 |
| 52w High: | 109.1935 |
| 52w Low: | 0.087 |
FSD Pharma Inc. is a biopharmaceutical research and development company, operating through its various subsidiaries. The firm's leading drug candidate, FSD-201, is currently undergoing Phase II clinical trials for the treatment of COVID-19 disease. Additionally, FSD Pharma is actively developing Lucid-PSYCH, a psychoactive molecule identified for its potential in addressing neuropsychiatric conditions such as depressive disorder. They are also advancing Lucid-MS, a proprietary new chemical entity which, in preclinical models, has demonstrated the capacity to prevent and reverse myelin degradation—the fundamental mechanism behind multiple sclerosis. Established in 1998, FSD Pharma Inc. is headquartered in Toronto, Canada.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 05 Aug 2026
InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's New $105 Million Facility Valuation, Potentially $420 Million with Completion of 3 Million Sq Ft Expansion - Video Available on Investmentpitch.com - TMX Newsfile
Sat, 06 Jun 2026
Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Wed, 14 Aug 2024
FSD Pharma Inc To Carry Out 1-for-65 Reverse Stock Split On August 15th, 2024 - Moomoo
Fri, 09 Aug 2024
FSD Pharma Announces Share Consolidation and Name Change - Yahoo Finance
Fri, 28 Jun 2024
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd. - Yahoo Finance
Mon, 17 Jul 2023
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201 - Business Wire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
